一项评估 Atezolizumab(联合或不联合贝伐珠单抗)治疗不可切除肝细胞癌和 Child-Pugh B7 和 B8 肝硬化患者的研究 (Kirros)
一项针对不可切除的肝细胞癌和 Child-Pugh B7 和 B8 肝硬化患者的 II 期、开放标签、多队列、多中心研究
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
研究概览
详细说明
This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic HCC who have Child-pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Rio Piedras、波多黎各、00935
- Pan American Center for Oncology Trials, LLC
-
-
-
-
Arizona
-
Tucson、Arizona、美国、85724
- University of Arizona Cancer Center
-
-
California
-
La Jolla、California、美国、92093
- UC San Diego Moores Cancer Center
-
Los Angeles、California、美国、90089-5601
- University of Southern California-Keck School of Medicine -1975 Zonal Ave
-
Newport Beach、California、美国、92663
- University of Southern California
-
Orange、California、美国、92868
- University of California Irvine Medical Center
-
Pasadena、California、美国、91105-2561
- California Liver Research Institute
-
Sacramento、California、美国、95817
- University of California Davis Medical Center
-
Stanford、California、美国、94305
- Stanford Health Care
-
Torrance、California、美国、90502-2006
- Harbor UCLA Medical Center
-
West Hollywood、California、美国、90048-2422
- Cedars Sinai Comprehensive Transplant Center
-
-
Connecticut
-
Hartford、Connecticut、美国、06106
- Hartford Healthcare Cancer Institute at Hartford Hospital
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20037
- George Washington University- Medical Faculty Associates
-
Washington D.C.、District of Columbia、美国、20422-0001
- Washington DC VA Medical Center
-
-
Florida
-
Orlando、Florida、美国、32806
- Orlando Health Inc.
-
-
Illinois
-
Chicago、Illinois、美国、60611-2908
- Northwestern University
-
Chicago、Illinois、美国、60612-4795
- University of Illinois Health Outpatient Care Center
-
Chicago、Illinois、美国、60637-1426
- The Duchossois Center for Advanced Medicine
-
-
Kentucky
-
Lexington、Kentucky、美国、40536-7001
- University of Kentucky - Markey Cancer Center
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70805
- LSU Health Baton Rouge
-
Baton Rouge、Louisiana、美国、70808-4300
- Our Lady of the Lake Cancer Institute
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- Beth Israel Deaconess Medical Center
-
Boston、Massachusetts、美国、02111
- Tufts Medical Center
-
-
Michigan
-
Detroit、Michigan、美国、48201
- Barbara Ann Karmanos Cancer Institute
-
Detroit、Michigan、美国、48202
- Henry Ford Health System
-
-
Missouri
-
Kansas City、Missouri、美国、64111
- Saint Luke?s Hospital of Kansas City
-
-
New Jersey
-
New Brunswick、New Jersey、美国、08901
- Rutgers Cancer Institute of New Jersey
-
Newark、New Jersey、美国、07103
- Rutgers Cancer Institute of New Jersey at University Hospital
-
-
New York
-
Mineola、New York、美国、11501-4064
- NYU Langone Hospital - Long Island
-
New York、New York、美国、10029
- Icahn School of Medicine at Mount Sinai
-
The Bronx、New York、美国、10467
- Montefiore Medical Center
-
The Bronx、New York、美国、10468-3904
- James J Peters Veterans Administration Medical Center - NAVREF
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204
- Levine Cancer Institute
-
-
Ohio
-
Dayton、Ohio、美国、45428-9000
- Dayton VA Medical Center - NAVREF - PPDS
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104-5020
- The University of Oklahoma Health Sciences Center
-
-
Oregon
-
Hillsboro、Oregon、美国、97124-5806
- Kaiser Permanente Westside Medical Center
-
Portland、Oregon、美国、97239-3011
- OHSU Knight Cancer Institute Hematology Oncology
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19107
- Jefferson Health Honickman Center
-
Pittsburgh、Pennsylvania、美国、15240
- Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS
-
-
Tennessee
-
Germantown、Tennessee、美国、38138-1762
- The West Clinic (East Campus)
-
Nashville、Tennessee、美国、37208-2918
- Nashville General Hospital at Meharry
-
-
Texas
-
Dallas、Texas、美国、75390-0001
- University of Texas Southwestern Medical Center
-
Dallas、Texas、美国、75246-2008
- Texas Oncology (Worth) - USOR
-
Dallas、Texas、美国、75203-1260
- Liver Institute at Methodist Dallas
-
Dallas、Texas、美国、75235
- Moody Outpatient Center ? Parkland Health
-
Denison、Texas、美国、75020-0084
- Texas Oncology - Denison Cancer Center
-
Houston、Texas、美国、77025-1669
- Kelsey Research Foundation
-
Houston、Texas、美国、77030-4211
- Michael E Debakey VA Medical Center - NAVREF - PPDS
-
-
Utah
-
Murray、Utah、美国、84107-5741
- Intermountain Healthcare
-
St. George、Utah、美国、84790
- Intermountain Cancer Center
-
-
Virginia
-
Falls Church、Virginia、美国、22042
- Inova Schar Cancer Institute
-
Richmond、Virginia、美国、23226-1925
- Bon Secours St. Mary's Hospital
-
Richmond、Virginia、美国、23298-5028
- VCU Medical Center North Hospital
-
-
Washington
-
Seattle、Washington、美国、98101
- Virginia Mason Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
General Inclusion Criteria:
- Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants
- Disease that is not amenable to curative surgical and/or locoregional therapies
- No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC
- Measurable disease (at least one untreated target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days prior to initiation of study treatment
- Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment
- Adequate hematologic and end-organ function
- Life expectancy of at least 12 weeks
- Female participants of childbearing potential must be willing to avoid pregnancy and egg donation
- Absolute neutrophil count (ANC) ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support
- Platelet count ≥ 50 × 109/L (50,000/μL) without transfusion
- Hemoglobin (Hb) ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL])
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal (ULN)
- Serum bilirubin ≤ 3 × ULN
- Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula)
- Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months
- International normalized ratio (INR) ≤2.3
General Exclusion Criteria:
- Pregnancy or breastfeeding
- Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
- Treatment with investigational therapy within 28 days prior to initiation of study treatment
- Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
- Treatment with systemic immunostimulatory agents
- Treatment with systemic immunosuppressive medication
- Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
- Inadequately controlled hypertension
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation
- Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded
- Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- Prior allogeneic stem cell or solid organ transplantation
- Actively listed for liver transplantation
- Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding
- A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
- Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment
- Hepatic encephalopathy is allowed if no active symptoms or stable within 3 months of study treatment
- History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS) is excluded from Cohort A only. TIPS is acceptable in Cohort B
- Diagnostic paracentesis is allowed. Therapeutic paracentesis: one large volume paracentesis prior to enrollment with diuretic controlled ascites is allowed.
- Participants with ascites controlled on diuretics are allowed
- History of spontaneous bacterial peritonitis within last 12 months
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Cohort A: Atezolizumab+Bevacizumab
Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator. |
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
其他名称:
Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) by IV infusion on Day 1 of each 21-day cycle.
其他名称:
|
|
实验性的:Cohort B: Atezolizumab
Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator. |
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants With Adverse Events (AEs)
大体时间:Baseline through the end of the study (up to approximately 36 months)
|
An AE is any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) in Cohorts A and B. |
Baseline through the end of the study (up to approximately 36 months)
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- ML44719
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.